ImaginAb
Clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
Launch date
Employees
Market cap
-
Enterprise valuation
€47—70m (Dealroom.co estimates Jun 2021.)
Inglewood California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$12.5m | Series A | ||
$21.0m | Series B | ||
| N/A | $5.3m | Late VC | |
$8.0m | Late VC | ||
$12.8m | Late VC | ||
| Total Funding | €54.2m | ||
Related Content
Recent News about ImaginAb
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.